公开(公告)号：EP2858672B1

公开(公告)日：2018-04-04

申请号：EP13800676.2

申请日：2013-06-06

申请人： Alkermes, Inc.

发明人： ALVAREZ, Juan ,  MCSWEENEY, Leslie, A.

IPC分类号： C12N15/62 ,  C07K14/47

CPC分类号： C07K14/55 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/4713 ,  C07K14/4727 ,  C07K14/50 ,  C07K14/54 ,  C07K14/5412 ,  C07K14/5443 ,  C07K14/545 ,  C07K14/57563 ,  C07K14/70503 ,  C07K14/71 ,  C07K14/7155 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/74 ,  C07K2319/91

摘要： The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof.

公开(公告)号：EP2727605B1

公开(公告)日：2018-04-04

申请号：EP12804683.6

申请日：2012-06-28

申请人： Theraly Pharmaceuticals Inc.

发明人： LEE, Sung Kwon ,  KIM, Won Bae ,  LEE, Seulki ,  KIM, Tae Hyung

IPC分类号： A61K47/30 ,  A61K38/22 ,  A61P3/10 ,  C07K14/575 ,  A61K47/60 ,  A61K9/00 ,  A61K47/02 ,  A61K47/26 ,  A61K9/20 ,  A61K9/48

CPC分类号： A61K47/02 ,  A61K9/0019 ,  A61K9/2018 ,  A61K9/2059 ,  A61K9/4858 ,  A61K9/4866 ,  A61K38/2278 ,  A61K47/26 ,  A61K47/60 ,  C07K14/57563

摘要： The present disclosure relates to an exendin-4 analogue PEGylated with polyethylene glycol or a derivative thereof, a preparation method, and a pharmaceutical composition for prevention or treatment of diabetes containing the same as an active ingredient. According to the present invention, the yield of an exendin-4 analogue can be increased via the selective PEGylation by using exendin-4 in which a cysteine is introduced into #40 site of the C-terminal, and treatment effect of medications can be increased, so that the exendin-4 analogue can be usefully applied as a composition for prevention or treatment of diseases caused by insulin hypersecretion.

公开(公告)号：EP2590997B1

公开(公告)日：2018-04-04

申请号：EP11804451.0

申请日：2011-07-08

申请人： Dana-Farber Cancer Institute, Inc.

发明人： WALENSKY, Loren, D. ,  BIRD, Gregory

IPC分类号： C07K14/605 ,  C07K14/575 ,  C07K14/62 ,  A61K38/26 ,  A61K38/22 ,  A61P3/10

CPC分类号： C07K14/605 ,  A61K38/00 ,  C07K14/575 ,  C07K14/57563

摘要： The present invention provides stably cross-linked insulionotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for preparing and evaluating the polypeptides of the invention.

公开(公告)号：EP2874639B1

公开(公告)日：2018-03-28

申请号：EP13799943.9

申请日：2013-06-06

申请人： Alkermes, Inc.

发明人： ALVAREZ, Juan ,  CHAMOUN, Jean ,  LOSEY, Heather, C.

IPC分类号： C12N15/62 ,  C07K14/47 ,  C07K14/575 ,  C07K14/715

CPC分类号： C07K14/55 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/4713 ,  C07K14/4727 ,  C07K14/50 ,  C07K14/54 ,  C07K14/5412 ,  C07K14/5443 ,  C07K14/545 ,  C07K14/57563 ,  C07K14/70503 ,  C07K14/71 ,  C07K14/7155 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/74 ,  C07K2319/91

摘要： The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof.

公开(公告)号：EP2406399B1

公开(公告)日：2018-02-14

申请号：EP10751262.6

申请日：2010-03-09

申请人： Bioatla, LLC

发明人： SHORT, Jay, M. ,  CHANG, Hwai, Wen ,  FREY, Gerhard ,  FROST, Gregory

IPC分类号： C12Q1/68 ,  C12P21/00 ,  C07K14/00 ,  A61K38/17

CPC分类号： C12N15/102 ,  A61K38/00 ,  C07K7/06 ,  C07K14/3153 ,  C07K14/47 ,  C07K14/575 ,  C07K14/57545 ,  C07K14/57563 ,  C12N9/16 ,  C12N9/50 ,  C12N9/6435 ,  C12N9/6459 ,  C12N9/6462 ,  C12N15/1058 ,  C12Y302/01035 ,  C12Y304/21007 ,  C12Y304/21069 ,  C12Y304/21073 ,  C12Y304/23015 ,  C12Y304/24029 ,  G01N33/54306 ,  G01N33/573 ,  G01N33/6845 ,  G01N33/6854 ,  Y02A50/473

摘要： A method of generating conditionally active biologic antibodies from parent antibodies, in particular therapeutic antibodies, which are more active at an aberrant physiological condition than at a normal physiological condition and which may reversibly or irreversibly inactivated at the wild type normal physiological condition. For example, evolved antibodies are may be less active or inactive at normal body temperature or pH, than at other aberrant body temperatures or at an aberrant pH.

公开(公告)号：EP2709653B1

公开(公告)日：2017-11-22

申请号：EP12773975.3

申请日：2012-04-19

申请人： The U.S.A. as represented by the Secretary, Department of Health and Human Services

发明人： CHIORINI, John, A. ,  PASQUALE, Giovanni, Di ,  MANNUCCI, Edoardo

IPC分类号： A61K38/22 ,  C12N15/861 ,  C07K14/575 ,  A61P3/10 ,  A61P3/04

CPC分类号： A61K35/76 ,  A61K35/761 ,  A61K38/1703 ,  A61K48/005 ,  A61K48/0075 ,  C07H21/04 ,  C07K14/48 ,  C07K14/57563 ,  C07K14/605 ,  C07K2319/055 ,  C07K2319/50 ,  C12N7/00 ,  C12N15/86 ,  C12N2750/14143

摘要： The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an AAV virion comprising an AAV vector that encodes an exendin-4 protein. Also provided are exendin-4 proteins and nucleic acid molecules that encode such exendin-4 proteins. Also provided are AAV vectors and AAV virions that encode an exendin-4 protein. One embodiment is an exendin-4 protein that is a fusion protein comprising an NGF secretory segment joined to the amino terminus of an exendin-4 protein domain.

公开(公告)号：EP3077419A4

公开(公告)日：2017-05-17

申请号：EP14868266

申请日：2014-12-04

申请人： INNOVATIVE TARGETING SOLUTIONS INC

发明人： GALLO MICHAEL ,  KANG JASPAL SINGH ,  PIGOTT CRAIG ROBIN ,  LIN ABBY YU CHEN

IPC分类号： C07K19/00 ,  C07K14/575 ,  C07K14/605 ,  C07K16/28 ,  C12N5/10 ,  C12N15/13 ,  C12N15/62 ,  C12N15/85 ,  C12Q1/68 ,  C40B40/02 ,  C40B50/06 ,  G01N33/567

CPC分类号： C07K16/2869 ,  A61K38/00 ,  C07K14/575 ,  C07K14/57563 ,  C07K14/605 ,  C07K16/28 ,  C07K2317/51 ,  C07K2317/526 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2318/10 ,  C07K2319/75 ,  C12N2510/00 ,  C12Q1/68 ,  C12Q1/6897 ,  C40B40/02 ,  C40B50/06 ,  G01N33/5008 ,  G01N33/567 ,  G01N2333/726 ,  G01N2500/10

摘要： Peptide-grafted antibodies having agonist activity against a Class B GPCR and their uses, and methods for identifying same. Mammalian cell lines for high-throughput screening for agonists of a Class B GPCR are also provided that comprise a stably integrated recombinant nucleic acid construct comprising a reporter gene under control of a cAMP responsive promoter, the reporter gene encoding a cell surface expressed protein, and a stably integrated recombinant nucleic acid construct comprising a sequence encoding a Class B GPCR under control of a constitutive promoter.

摘要翻译： 具有针对B类GPCR的激动剂活性的肽移植抗体及其用途，以及鉴定它们的方法。 还提供了用于B类GPCR激动剂的高通量筛选的哺乳动物细胞系，其包含稳定整合的重组核酸构建体，所述稳定整合的重组核酸构建体包含处于cAMP响应性启动子控制下的报道基因，编码细胞表面表达蛋白的报道基因和 包含编码在组成型启动子控制下的B类GPCR的序列的稳定整合的重组核酸构建体。

公开(公告)号：EP3157949A1

公开(公告)日：2017-04-26

申请号：EP15731876.7

申请日：2015-06-17

申请人： Sanofi SA

发明人： HAACK, Torsten ,  STENGELIN, Siegfried ,  EVERS, Andreas ,  WAGNER, Michael ,  HENKEL, Bernd

IPC分类号： C07K14/575 ,  A61K38/22 ,  A61P3/10

CPC分类号： C07K14/605 ,  A61K38/00 ,  A61K45/06 ,  C07K14/57563

摘要： The present invention relates to glucagon receptor agonists and their medical use, for example in the treatment of severe hypoglycemia.

摘要翻译： 本发明涉及胰高血糖素受体激动剂及其医学用途，例如用于治疗严重低血糖症。

公开(公告)号：EP3019533A4

公开(公告)日：2017-04-12

申请号：EP14823623

申请日：2014-07-11

申请人： THE CALIFORNIA INST FOR BIOMEDICAL RES

发明人： WANG FENG ,  ZHANG YONG ,  WANG YING ,  LIU YAN ,  SCHULTZ PETER G

IPC分类号： C07K16/46 ,  A61K39/395 ,  A61K47/65 ,  A61P35/00 ,  C07K16/10 ,  C12N15/62

CPC分类号： C07K16/2863 ,  A61K39/395 ,  A61K47/65 ,  A61K47/6889 ,  A61K2039/505 ,  C07K14/43522 ,  C07K14/47 ,  C07K14/505 ,  C07K14/535 ,  C07K14/57563 ,  C07K14/5759 ,  C07K14/605 ,  C07K14/61 ,  C07K14/64 ,  C07K14/70503 ,  C07K14/811 ,  C07K16/1027 ,  C07K16/2866 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2318/10 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/50 ,  C07K2319/55 ,  C07K2319/73

摘要： Disclosed herein are immunoglobulin fusion proteins that have a first antibody region attached to an extender fusion region. The extender fusion region contains a therapeutic agent and a beta strand secondary structure. The extender fusion region may contain 7 or fewer consecutive amino acids based on or derived from an ultralong CDR3. Alternatively, the extender fusion region contains a rigid stalk protein structure, but does not contain an amino acid sequence based on or derived from an ultralong CDR3. The extender fusion region may also have one or more linkers or proteolytic cleavage sites. The immunoglobulin fusion proteins may have additional therapeutic agents and extender fusion regions. Also disclosed herein are pharmaceutical compositions of immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.

公开(公告)号：EP3121194A1

公开(公告)日：2017-01-25

申请号：EP16180577.5

申请日：2013-03-14

申请人： Innovative Targeting Solutions Inc.

发明人： GALLO, Michael ,  KANG, Jaspal, Singh ,  PIGOTT, Craig Robin

IPC分类号： C07K14/575 ,  C07K14/605 ,  C12N15/62 ,  C12N15/85 ,  C07K14/52 ,  C07K14/54 ,  C07K14/71 ,  C07K14/78 ,  C07K16/28 ,  C07K16/32 ,  C07K14/47 ,  C07K16/00

CPC分类号： C12N15/625 ,  C07K14/4723 ,  C07K14/522 ,  C07K14/5421 ,  C07K14/57563 ,  C07K14/605 ,  C07K14/71 ,  C07K14/78 ,  C07K16/00 ,  C07K16/2839 ,  C07K16/2866 ,  C07K16/2869 ,  C07K16/32 ,  C07K2317/565 ,  C07K2318/10 ,  C07K2319/00 ,  C07K2319/01 ,  C07K2319/03 ,  C12N15/62 ,  C12N15/85 ,  C12N2800/30

摘要： Methods of generating fusion protein variants are provided that comprise introducing sequence diversity at the junction region or regions in the fusion and allows for the generation of variants having a desired activity. Examples include immunoglobulins comprising a domain or polypeptide inserted into, or replacing, a CDR. Also provided are polynucleotides encoding a fusion protein and comprising two or more RSSs, and compositions and host cells comprising same, as well as fusion proteins variants produced by the described methods.

摘要翻译： 提供产生融合蛋白变体的方法，其包括在融合中的连接区域或区域处引入序列多样性，并允许产生具有所需活性的变体。 实例包括免疫球蛋白，其包含插入或替代CDR的结构域或多肽。 还提供了编码融合蛋白并包含两个或更多个RSS的多核苷酸，以及包含其的组合物和宿主细胞，以及通过所述方法产生的融合蛋白变体。